Arrowhead Pharmaceuticals (NASDAQ:ARWR) outlined a slate of expected clinical data updates during a discussion at the Leerink ...

Alnylam Pharmaceuticals (NasdaqGS:ALNY) has signed a multi year research collaboration with Tenaya Therapeutics focused on RNAi based therapeutics for cardiovascular diseases. The agreement covers up ...

Balancing nitrogen use is critical for maximizing crop yield while minimizing environmental and economic costs. A new approach integrates drone-based multispectral imaging with machine learning to ...

This week's round-up of pharma licensing deals features alliances involving Tenaya Therapeutics, Sino Bio, Antengene, and A2A ...

Phase 1/2 RESTORE-MASH trial will evaluate safety, pharmacokinetics, and pharmacodynamics of TGM-312 in healthy volunteers and MASH ...

"2025 proved that our technology delivers, not in the distant future, but right now," says Tropic CEO Gilad Gershon.

Twenty years after scientists found that double-stranded RNA can turn off genes, a drug based on the discovery, known as RNA interference, has been approved. The U.S. Food & Drug Administration has ...

Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric cancer ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the Investors section of the Company’s ...

Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, ...

Three Vietnamese researchers in Hong Kong have solved a 20-year puzzle in molecular biology that could reshape how scientists ...

Agreement Combines Tenaya’s Expertise in Identification and Validation ofGenetic Heart Disease Targets with Alnylam’s Ability ...